Ultragenyx Secures First Gene Therapy Approval and Priority Review Voucher, Lifting RARE Stock 6% After-Hours
核心洞察
Ultragenyx (RARE) received its first gene therapy (搜索) approval from the FDA, driving the stock up 6% in after-hours trading.
The approval also granted Ultragenyx a Priority Review Voucher, which one Stocktwits user estimated to be worth approximately $200 million.
Retail sentiment on Stocktwits improved from "bullish" to "extremely bullish," with some users speculating about a potential big-pharma buyout of Ultragenyx.
Ultragenyx Pharmaceutical Inc. (RARE) secured its first gene therapy (搜索) approval from the U.S. Food and Drug Administration (FDA), a milestone that sent the company's stock up 6% in after-hours trading. The approval also came with a Priority Review Voucher, a transferable asset that can be used to expedite FDA review of a future drug application or sold to another company.
Retail investor reaction on Stocktwits reflected growing enthusiasm around the announcement. Retail sentiment around RARE stock improved from "bullish" to "extremely bullish" over the past 24 hours, while message volume stayed at "normal" levels. One Stocktwits user projected the stock could rise as high as $30 following the approval, while another noted that the Priority Review Voucher Ultragenyx received with the approval alone is worth about $200 million. A third user voiced hopes of a big-pharma buyout of Ultragenyx.
The approval marks a significant regulatory achievement for Ultragenyx, which has now gained 14% year-to-date. The Priority Review Voucher adds further financial and strategic value to the milestone, as such vouchers can be monetized or applied to accelerate future regulatory submissions.
The company's stock performance in the days leading up to the decision had been mixed. In a prior report, RARE stock had clocked two consecutive days of losses ahead of the weekend FDA decision, with retail sentiment remaining within bullish territory and message volume at normal levels. One Stocktwits user expressed frustration at the stock selloff ahead of the potential approval, while another noted that the stock had near-term catalysts beyond the weekend FDA decision as well. At that time, RARE stock had risen 11% year-to-date.
The FDA approval and accompanying Priority Review Voucher represent a pivotal moment for Ultragenyx, positioning the company within the gene therapy (搜索) landscape and drawing heightened attention from both retail and institutional investors.